178 related articles for article (PubMed ID: 33636616)
21. Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis.
Burt RK; Balabanov R; Han X; Sharrack B; Morgan A; Quigley K; Yaung K; Helenowski IB; Jovanovic B; Spahovic D; Arnautovic I; Lee DC; Benefield BC; Futterer S; Oliveira MC; Burman J
JAMA; 2015 Jan; 313(3):275-84. PubMed ID: 25602998
[TBL] [Abstract][Full Text] [Related]
22. Long-term evolution of multiple sclerosis disability in the treatment era.
; Cree BA; Gourraud PA; Oksenberg JR; Bevan C; Crabtree-Hartman E; Gelfand JM; Goodin DS; Graves J; Green AJ; Mowry E; Okuda DT; Pelletier D; von Büdingen HC; Zamvil SS; Agrawal A; Caillier S; Ciocca C; Gomez R; Kanner R; Lincoln R; Lizee A; Qualley P; Santaniello A; Suleiman L; Bucci M; Panara V; Papinutto N; Stern WA; Zhu AH; Cutter GR; Baranzini S; Henry RG; Hauser SL
Ann Neurol; 2016 Oct; 80(4):499-510. PubMed ID: 27464262
[TBL] [Abstract][Full Text] [Related]
23. Mitoxantrone in relapsing-remitting and rapidly progressive multiple sclerosis: Ten-year clinical outcomes post-treatment with mitoxantrone.
Foo EC; Russell M; Lily O; Ford HL
Mult Scler Relat Disord; 2020 Sep; 44():102330. PubMed ID: 32599468
[TBL] [Abstract][Full Text] [Related]
24. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis.
Shirani A; Zhao Y; Karim ME; Evans C; Kingwell E; van der Kop ML; Oger J; Gustafson P; Petkau J; Tremlett H
JAMA; 2012 Jul; 308(3):247-56. PubMed ID: 22797642
[TBL] [Abstract][Full Text] [Related]
25. Low-fat, plant-based diet in multiple sclerosis: A randomized controlled trial.
Yadav V; Marracci G; Kim E; Spain R; Cameron M; Overs S; Riddehough A; Li DK; McDougall J; Lovera J; Murchison C; Bourdette D
Mult Scler Relat Disord; 2016 Sep; 9():80-90. PubMed ID: 27645350
[TBL] [Abstract][Full Text] [Related]
26. Association of Intrathecal Immunoglobulin G Synthesis With Disability Worsening in Multiple Sclerosis.
Gasperi C; Salmen A; Antony G; Bayas A; Heesen C; Kümpfel T; Linker RA; Paul F; Stangel M; Tackenberg B; Bergh FT; Warnke C; Weber F; Wiendl H; Wildemann B; Zettl UK; Ziemann U; Zipp F; Tumani H; Gold R; Hemmer B;
JAMA Neurol; 2019 Jul; 76(7):841-849. PubMed ID: 31034002
[TBL] [Abstract][Full Text] [Related]
27. Changes in the Risk of Reaching Multiple Sclerosis Disability Milestones In Recent Decades: A Nationwide Population-Based Cohort Study in Sweden.
Beiki O; Frumento P; Bottai M; Manouchehrinia A; Hillert J
JAMA Neurol; 2019 Jun; 76(6):665-671. PubMed ID: 30882868
[TBL] [Abstract][Full Text] [Related]
28. Vitamin D supplementation reduces relapse rate in relapsing-remitting multiple sclerosis patients treated with natalizumab.
Laursen JH; Søndergaard HB; Sørensen PS; Sellebjerg F; Oturai AB
Mult Scler Relat Disord; 2016 Nov; 10():169-173. PubMed ID: 27919484
[TBL] [Abstract][Full Text] [Related]
29. Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis.
Simpson S; Taylor B; Blizzard L; Ponsonby AL; Pittas F; Tremlett H; Dwyer T; Gies P; van der Mei I
Ann Neurol; 2010 Aug; 68(2):193-203. PubMed ID: 20695012
[TBL] [Abstract][Full Text] [Related]
30. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
[TBL] [Abstract][Full Text] [Related]
31. Longitudinal follow-up of "benign" multiple sclerosis at 20 years.
Sayao AL; Devonshire V; Tremlett H
Neurology; 2007 Feb; 68(7):496-500. PubMed ID: 17296915
[TBL] [Abstract][Full Text] [Related]
32. A low vitamin D status at diagnosis is associated with an early conversion to secondary progressive multiple sclerosis.
Muris AH; Rolf L; Broen K; Hupperts R; Damoiseaux J; Smolders J
J Steroid Biochem Mol Biol; 2016 Nov; 164():254-257. PubMed ID: 26598277
[TBL] [Abstract][Full Text] [Related]
33. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.
Trojano M; Butzkueven H; Kappos L; Wiendl H; Spelman T; Pellegrini F; Chen Y; Dong Q; Koendgen H; Belachew S;
Mult Scler Relat Disord; 2018 Aug; 24():11-19. PubMed ID: 29860197
[TBL] [Abstract][Full Text] [Related]
34. Serum 25-hydroxyvitamin D levels in multiple sclerosis patients from the north of Portugal.
Bettencourt A; Boleixa D; Reguengo H; Samões R; Santos E; Oliveira JC; Silva B; Costa PP; da Silva AM
J Steroid Biochem Mol Biol; 2018 Jun; 180():137-141. PubMed ID: 28951256
[TBL] [Abstract][Full Text] [Related]
35. Latitude, sun exposure and vitamin D supplementation: associations with quality of life and disease outcomes in a large international cohort of people with multiple sclerosis.
Jelinek GA; Marck CH; Weiland TJ; Pereira N; van der Meer DM; Hadgkiss EJ
BMC Neurol; 2015 Aug; 15():132. PubMed ID: 26243188
[TBL] [Abstract][Full Text] [Related]
36. Silent progression in disease activity-free relapsing multiple sclerosis.
; Cree BAC; Hollenbach JA; Bove R; Kirkish G; Sacco S; Caverzasi E; Bischof A; Gundel T; Zhu AH; Papinutto N; Stern WA; Bevan C; Romeo A; Goodin DS; Gelfand JM; Graves J; Green AJ; Wilson MR; Zamvil SS; Zhao C; Gomez R; Ragan NR; Rush GQ; Barba P; Santaniello A; Baranzini SE; Oksenberg JR; Henry RG; Hauser SL
Ann Neurol; 2019 May; 85(5):653-666. PubMed ID: 30851128
[TBL] [Abstract][Full Text] [Related]
37. α-Linolenic acid is associated with MRI activity in a prospective cohort of multiple sclerosis patients.
Bjornevik K; Myhr KM; Beiske A; Bjerve KS; Holmøy T; Hovdal H; Midgard R; Riise T; Wergeland S; Torkildsen Ø
Mult Scler; 2019 Jun; 25(7):987-993. PubMed ID: 29862891
[TBL] [Abstract][Full Text] [Related]
38. Late-onset and young-onset relapsing-remitting multiple sclerosis: evidence from a retrospective long-term follow-up study.
D'Amico E; Patti F; Zanghì A; Chisari CG; Lo Fermo S; Zappia M
Eur J Neurol; 2018 Dec; 25(12):1425-1431. PubMed ID: 29956427
[TBL] [Abstract][Full Text] [Related]
39. [Influence of acute aggravations on the development of long-term handicap in relapsing remitting multiple sclerosis: a clinical study in 99 patients].
Gaillard N; Fabro-Perray P; Faillie JL; Le Bayon A; Castelnovo G; Dupeyron A; Froger J; Pelissier J; Labauge P
Rev Neurol (Paris); 2007 Jan; 163(1):72-81. PubMed ID: 17304175
[TBL] [Abstract][Full Text] [Related]
40. T2 lesions and rate of progression of disability in multiple sclerosis.
Mostert JP; Koch MW; Steen C; Heersema DJ; De Groot JC; De Keyser J
Eur J Neurol; 2010 Dec; 17(12):1471-5. PubMed ID: 20500805
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
